Tagraxofusp - Stemline Therapeutics

Drug Profile

Tagraxofusp - Stemline Therapeutics

Alternative Names: Diphtheria-toxin-interleukin-3-fusion-protein; DT(388)IL3; DT-388-IL-3; DT-IL-3; ELZONRIS; SL-401

Latest Information Update: 16 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Texas A&M University
  • Developer Stemline Therapeutics
  • Class Antineoplastics; Immunotherapies; Immunotoxins; Recombinant fusion proteins
  • Mechanism of Action Interleukin 3 receptor alpha subunit modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase I/II Multiple myeloma; Myelodysplastic syndromes; Myeloproliferative disorders
  • Preclinical Haematological malignancies; Hairy cell leukaemia; Systemic scleroderma
  • No development reported Chronic myeloid leukaemia; Lymphoma

Most Recent Events

  • 08 Nov 2018 Stemline Therapeutics announces intention to submit MAA to EMA in the first quarter of 2019
  • 08 Nov 2018 Stemline Therapeutics plans to launch tagraxofusp for Blastic plasmacytoid dendritic cell neoplasm
  • 13 Aug 2018 FDA assigns PDUFA action date of 21/02/2019 for tagraxofusp for Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top